NeuExcell Raises $10 Million For Gene Therapies Aimed at Neurodegenerative Repair
publication date: Sep 2, 2021
NeuExcell Therapeutics, a Pennsylvania-Shanghai gene therapy company focused on neurodegenerative diseases, completed a $10+ million Series Pre-A financing from China investors. Based on the scientific work of the company's co-founder and Chief Scientific Advisor, Prof. Gong Chen, NeuExcell has developed a neuron repair technology via in vivo astrocyte-to-neuron conversion. The technology delivers neural transcription factor(s) using an adeno-associated virus (AAV). The round was led by Co-Win Ventures and included YuanBio, Oriza Seed, Tsingyuan and InnoAngel. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.